Trial Profile
Radioligand therapy of 177Lu-PSMA-617 in prostate cancer patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2018
Price :
$35
*
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary) ; Gallium (68Ga) gozetotide
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Dec 2018 New trial record